Abcellera Biologics Inc ABCL

$11.82 +0.45 (3.96%)

Valuation

Market cap
3,624,142,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,032,500
Avg volume
5,347,412
Day's range
$11.08 – $11.90
Shares out
306,611,000
Stochastic %K
42%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

XxZeeMoneyxX Oct 25, 11:30 PM
$ABCL let’s see the rocket!! 🚀
0 replies
ViperV22 Oct 25, 10:58 PM
$ABCL
0 replies
Stocktradesmoon Oct 25, 10:35 PM
$ABCL 👀 $MRNA $PFE $SLS $JNJ 🚨🚨🚨BREAKING NEWS: HOPEFULLY YOU ALL BOUGHT THE DIP LAST WEEK!!! HUGE BREAKOUT COMING NEXT WEEK STARTING MONDAY!!!! MARK THIS POST. HUGE DATA RELEASED LAST NIGHT SATURDAY OCT. 24th!!!!! (HONESTLY I CAN’T BELIEVE THAT INVESTORS AREN’T TALKING ABOUT IT YET!!!!) EXCUSE MY LANGUAGE BUT THIS IS A BIG F***** DEAL!!! $ABCL 🚨 — HUGE NEW PHASE 3 DATA FOR T-CELL ENGAGERS! 🧬🔥 Amgen just released detailed results from its Phase 3 DeLLphi-305 trial at ESMO 2026, and the numbers are incredible. 💥 58% reduction in the risk of death 💥 Median overall survival: 21.1 months vs. 12.7 months 💥 One-year survival: 79% vs. 53% 💥 Progression-free survival: 7.4 months vs. 1.9 months This is a T-cell engager treating one of the most aggressive forms of lung cancer! The trial’s success was announced in September, but these detailed survival numbers were released TODAY, October 24.
2 replies
grncandle Oct 25, 10:02 PM
$FBIO & $ABCL Green<<
0 replies
Jack_Danielss Oct 25, 9:57 PM
$ABCL any news?
1 replies
AXMO Oct 25, 9:41 PM
$ABCL https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-mltx-dropped-what-is-driving-att/amp
0 replies
Stocktradesmoon Oct 25, 9:19 PM
$ABCL $MRNA $PFE $LLY $AMGN $ABCL 🚨👏👏👏👀 News Out 🗞️!!! 🔥 We are in BREAK-OUT Mode 👀 Chart 📈 Attached. WAVE 5 Price Target 🎯 $21 🔥!!! $ABCL One injection followed by 4 weeks later, 37.0% of patients had flushing completely disappear. Placebo: 2.2% 💉 - Patients with 90% or more reduction: 60.9% vs placebo 8.7% (Phase 2, 92 people, 600mg single dose) - Difference from placebo widened from 2.6 episodes/day (week 1) to 5.5 episodes/day (week 4) - 84% of patients responded &much/quite improved (placebo 27%) - 12 healthy postmenopausal women received 3 injections at 4-week intervals, and average liver values up to Phase 2 were similar to placebo. No gastrointestinal or liver abnormality signals - Half-life about 24 days, under development as monthly injection. Headache more frequent at 28.2% vs 13.0%, but mostly mild!
1 replies
Stocktradesmoon Oct 25, 9:05 PM
$ABCL $MRNA $PFE $LLY $SLS $ABCL The squeeze potential here is real imo. As of july 31 the stock had 23.6% of the float short and 9.7 days to cover. Probably since the company switched from service for fee to completely bet on themselves and people betting against the Q2 print. Latest insider buys • Aug 14: CFO Andrew Booth bought 37,200 shares at $10.32 (~$384K). • Aug 18: Director John Montalbano bought 10,000 shares at $11.03 (~$110K). • Aug 12: Hayden bought 46,387 shares at $10.37 (~$481K). No insider selling as of latest 6 months and good data readout so far as management tightens the burn rate per quarter. I’m betting the daily wedge plays out and put my money where my mouth is. Next objective will be breaking $12,86 and finally testing that $15 level imo. Once again I go all in! All in on management taking this home.
1 replies